Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

Phase 2

Completed

• Conditions: Idiopathic Pulmonary Fibrosis
• Interventions: Drug: zileuton; Drug: azathioprine/prednisone

• Registration Number: NCT00262405
• Lead Sponsor: University of Michigan

Brief Summary

Open label trial of zileuton compared to azathioprine/prednisone for patients with idiopathic pulmonary fibrosis. Study subjects will undergo a detailed clinical, radiographic, and physiologic assessment at baseline. Subjects will be monitored off treatment for three months for changes in symptoms and physiology. Subjects will then be randomized to six months of treatment with zileuton or azathioprine/prednisone. The primary endpoint of this trial is change in LTB4 levels in bronchoalveolar lavage fluid following six months of treatment. Secondary endpoints are progression free survival, change in dyspnea, change in quality of life, and change in physiology.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-01
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-12-02
• Study First Posted: 2005-12-06
• Primary Completion: 2007-05
• Study Completion: 2007-05
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-02
• Last Update Posted: 2015-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

• Diagnosis of idiopathic pulmonary fibrosis
• Taking < 15 mg prednisone for at least 30 days prior to screening
• Age 35-80, inclusive
• Able to understand a written informed consent and comply with the study protocol

Exclusion Criteria

• Significant environmental exposure
• Diagnosis of collagen vascular disease
• Evidence of active infection
• Clinically significant cardiac disease Myocardial infarction, coronary artery bypass or angioplasty within 6mo Unstable angina pectoris Congestive heart failure requiring hospitalization within 6 months Uncontrolled arrhythmia
• Poorly controlled or severe diabetes mellitus
• Pregnancy or lactation
• Women of childbearing potential not using a medically approved means of contraception (i.e. oral contraceptives, intrauterine devices, diaphragm, Norplant)
• Current enrollment in another experimental protocol

Physiologic Criteria:

• FEV1/FVC < 0.60

Laboratory Criteria:

• Total bilirubin > 1.5 X upper limit normal
• AST or ALT > 3X upper limit normal
• Alkaline phosphatase > 3X upper limit normal
• White blood cell count < 2,500/mm3
• Hematocrit < 30%
• Platelets < 100,000/mm3
• Prothrombin time INR > 1.5

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
zileuton	zileuton	Zileuton
azathioprine/prednisone	azathioprine/prednisone	azathioprine/prednisone

Primary Outcome Measures

Name	Time	Method
LTB4 level in BAL	6 months

Secondary Outcome Measures

Name	Time	Method
CRP score	6 months

Trial Locations

Locations (1)

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States